Michelson Diagnostics, a medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces that data showing significant improvement in the diagnosis of basal-cell carcinoma (BCC) using its VivoSight multibeam OCT scanner will be presented at the World Congress of Dermatology (Vancouver, June 8-13). In addition to being an efficient, non-invasive way to diagnose BCC and other non-melanoma skin cancers, using the VivoSight OCT scanner has the potential to reduce biopsies and surgery, thereby reducing scarring for patients.

To view the full article please click here